Skip to main content

View full-text article in PMC

. 2017 Nov 7;23(41):7415–7424. doi: 10.3748/wjg.v23.i41.7415

Table 4.

Survival rates of hepatocellular carcinoma patients in different groups

Group	OS rate (%)					RFS rate (%)
Group	1 yr	2 yr	3 yr	4 yr	P	1 yr	2 yr	3 yr	4 yr	P
MVI (-), TACE (-)	98.8	91.5	82.8	82.8	0.872	80.7	70.1	61.2	55.9	0.974
MVI (-), TACE (+)	94.2	91.9	87.6	87.6	0.872	83.0	71.8	61.9	NA	0.974
MVI (+), TACE (-)	81.3	65.7	58.8	53.9	0.019	52.0	41.1	33.7	28.4	0.002
MVI (+), TACE (+)	92.7	86.5	73.1	67.5	0.019	72.1	58.3	54.9	30.9	0.002

OS: Overall survival; RFS: Recurrence-free survival; MVI: Microvascular invasion; TACE: Transcatheter arterial chemoembolization.